95,402 Shares in The Chemours Company (NYSE:CC) Bought by Advisors Asset Management Inc.

Advisors Asset Management Inc. acquired a new stake in The Chemours Company (NYSE:CC - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 95,402 shares of the specialty chemicals company's stock, valued at approximately $1,939,000. Advisors Asset Management Inc. owned 0.06% of Chemours at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Burney Co. boosted its stake in Chemours by 0.3% in the 1st quarter. Burney Co. now owns 197,046 shares of the specialty chemicals company's stock valued at $5,174,000 after purchasing an additional 601 shares during the period. KBC Group NV boosted its position in shares of Chemours by 19.5% in the third quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company's stock valued at $91,000 after acquiring an additional 728 shares during the period. Blue Trust Inc. grew its stake in shares of Chemours by 166.9% in the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after acquiring an additional 731 shares in the last quarter. Arizona State Retirement System increased its position in Chemours by 2.1% during the second quarter. Arizona State Retirement System now owns 41,657 shares of the specialty chemicals company's stock worth $940,000 after acquiring an additional 863 shares during the period. Finally, New Covenant Trust Company N.A. acquired a new stake in Chemours in the 1st quarter worth about $29,000. 76.26% of the stock is owned by institutional investors.

Chemours Price Performance

Shares of CC stock traded up $0.41 on Monday, reaching $21.94. The company had a trading volume of 1,518,219 shares, compared to its average volume of 1,577,826. The stock has a market capitalization of $3.28 billion, a PE ratio of 43.88 and a beta of 1.75. The company has a quick ratio of 0.92, a current ratio of 1.73 and a debt-to-equity ratio of 6.05. The business's 50-day moving average is $19.47 and its 200 day moving average is $21.44. The Chemours Company has a one year low of $15.10 and a one year high of $32.70.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.32 by $0.08. The business had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The firm's revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.64 EPS. Equities research analysts forecast that The Chemours Company will post 1.35 EPS for the current fiscal year.

Chemours Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.00 dividend on an annualized basis and a yield of 4.56%. Chemours's dividend payout ratio is currently 200.00%.

Insider Buying and Selling

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the transaction, the senior vice president now directly owns 16,645 shares in the company, valued at approximately $343,552.80. This represents a 31.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.47% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. The Goldman Sachs Group decreased their target price on shares of Chemours from $29.00 to $23.00 and set a "neutral" rating on the stock in a research report on Tuesday, September 3rd. Royal Bank of Canada lowered their price objective on Chemours from $28.00 to $25.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. Morgan Stanley cut their target price on Chemours from $30.00 to $25.00 and set an "equal weight" rating for the company in a research report on Tuesday, November 5th. UBS Group decreased their price target on Chemours from $30.00 to $28.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Chemours from $25.00 to $18.00 and set a "neutral" rating for the company in a research report on Tuesday, August 6th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Chemours has a consensus rating of "Hold" and a consensus price target of $24.88.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.